GLOW is a pre-formulated peptide blend combining three of the most investigated repair peptides in modern preclinical literature: GHK-Cu (50mg), TB-500 (10mg), and BPC-157 (10mg) in a single lyophilized vial . The blend reduces three reconstitution steps to one and fixes the ratio of the three peptides in a defined stoichiometry for research applications .

The name “GLOW” refers to the mechanistic rationale of the formulation, not cosmetic marketing claims. Each component targets a distinct phase of the tissue repair cascade, creating a theoretically complementary approach to studying regeneration, inflammation, and extracellular matrix remodeling .

Each vial contains lyophilized powder tested to ≥99% purity by HPLC per component, with sequence confirmed by mass spectrometry. A lot-specific Certificate of Analysis (COA) is available upon request.

Best for: Tissue repair research, wound healing studies, dermatological research, inflammation pathway investigations, and regenerative medicine applications.

Component Breakdown

Note: The characteristic deep blue color visible after successful reconstitution comes from the GHK-Cu chelate and serves as the most important visual quality indicator of the entire blend .

The Three-Phase Repair Cascade

The GLOW blend is designed around a mechanistically coherent three-stage repair model :

Phase 1: The Repair Signal (BPC-157)

Before any tissue rebuilds, the body must issue the instruction, flag damage, and modulate inflammation. BPC-157 upregulates growth hormone receptors on tendon fibroblasts, modulates nitric oxide pathways, interacts with the VEGF system, and demonstrates cytoprotective activity across multiple tissues . Without a strong repair signal, nothing else in the cascade has a reason to start.

Phase 2: The Infrastructure (TB-500)

A signal without infrastructure cannot rebuild tissue. Cells must migrate to the damaged site, and new blood vessels must form to supply emerging tissue. TB-500 governs how cells move and where they position themselves during repair by sequestering G-actin and controlling filament formation . Preclinical research supports its role in angiogenesis, wound closure, and muscle and connective tissue regeneration . This is the stage most single-peptide protocols underserve.

Phase 3: The Remodeling (GHK-Cu)

Even with a strong signal and adequate infrastructure, tissue that gets rebuilt is not automatically durable tissue. Collagen must be organized, and the extracellular matrix must be coherent. GHK-Cu stimulates collagen and glycosaminoglycan synthesis, modulates matrix metalloproteinase activity, and carries anti-inflammatory and antioxidant properties . Research reports that GHK-Cu appears to influence expression of over 4,000 human genes, with effects oriented toward restoring cellular function to healthier baselines . The structural quality of repair lives in this phase.

Key Research Applications

• Tissue Repair & Wound Healing: Investigated for accelerated wound closure, enhanced re-epithelialization, and improved tissue regeneration outcomes in preclinical models 

• Dermatological Research: Studied for collagen synthesis, skin density improvement, wrinkle reduction, and overall skin integrity 

• Inflammation Studies: Explored for modulation of inflammatory cytokines, NF-κB pathway inhibition, and resolution of chronic inflammation 

• Connective Tissue Research: Investigated for tendon, ligament, and muscle repair through complementary mechanisms 

• Gastrointestinal Research: BPC-157 component studied for mucosal healing and gut barrier integrity 

• Angiogenesis Studies: TB-500 component examined for new blood vessel formation and tissue perfusion 

Synergy Rationale

Each peptide in the GLOW blend addresses a different bottleneck in the repair cascade. No single peptide covers all three phases :

The combination is theoretically additive (not redundant) because each peptide attacks a different node of shared signaling pathways . Run the cascade through each compound in isolation, and the repair process hits whatever ceiling the downstream phases happen to be capped at .

Specifications

Reconstitution Guidance

Reconstitute the GLOW blend with bacteriostatic water (0.9% benzyl alcohol) for research use. Direct diluent gently down the inner wall of the vial rather than onto the lyophilized cake. Swirl slowly until fully dissolved — do not shake.

Critical visual indicator: After successful reconstitution, the solution should display a characteristic deep blue color from the GHK-Cu copper chelate. If the solution lacks this blue tint, it may indicate incomplete dissolution or product degradation .

Many investigators use 2-5 mL of bacteriostatic water per vial. For a 70mg total peptide vial (50/10/10), reconstituting with:

• 5 mL yields ~10mg/mL total peptides (7.14mg GHK-Cu + 1.43mg TB-500 + 1.43mg BPC-157 per 0.1 mL)

• 2.5 mL yields ~28mg/mL total peptides

For best results, aliquot the reconstituted solution into single-use tubes immediately to avoid repeated freeze-thaw cycles, which is the single largest contributor to peptide degradation.

Storage & Stability

Before Reconstitution: Store the unopened, lyophilized vial at −20°C in a desiccated, light-protected environment. Stable under these conditions for the shelf-life indicated on the certificate of analysis.

After Reconstitution: Store working solutions at 2–8°C for short-term use (up to 7-14 days). For long-term storage, prepare single-use aliquots and freeze at −20°C. Avoid repeated freeze-thaw cycles.

Quality Assurance

Every lot of GLOW blend undergoes comprehensive release testing against internal specifications, including:

• HPLC for purity confirmation per component (≥99%)

• Mass spectrometry for identity verification of each peptide

• Visual inspection of vial integrity

• Post-reconstitution color verification (blue GHK-Cu indicator)

Each vial is coded with a lot number that links directly to release testing documentation. A lot-specific Certificate of Analysis (COA) is available upon request.

Important Research Notes

No Published Human Trials for the GLOW Combination: No peer-reviewed study has tested the three-peptide combination (GHK-Cu + TB-500 + BPC-157) in vitro or in vivo . The synergy hypothesis is mechanistically derived from individual component data and not experimentally validated for the combination. There are no published human clinical trials on this specific three-compound combination .

Component-Level Evidence Summary:

WADA Status: Both BPC-157 and TB-500 are explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List. GHK-Cu is not currently listed but falls under general prohibitions on unapproved substances in some contexts .

Regulatory Status: GLOW is not FDA-approved for any medical use. It is classified as a research chemical and is not intended for human consumption. Compounded versions are available through select pharmacies under physician supervision, but Pyrex Labs sells this product strictly for laboratory and in-vitro research use.

Safety Note on GHK-Cu: The amount of copper in GHK-Cu is less than 20% actual copper. The toxic threshold for copper is 10mg. Typical research doses contain approximately 2.5mg of GHK-Cu total, making copper toxicity highly unlikely . The primary reported limitation with higher doses is injection site reaction and pain after a few hours, not systemic toxicity .

Related Products from Pyrex Labs

Researchers who order GLOW blend frequently also purchase individual components for comparative studies:

• GHK-Cu (5mg / 10mg) – Individual copper peptide

• TB-500 (5mg / 10mg) – Individual thymosin beta-4 fragment

• BPC-157 (5mg / 10mg) – Individual body protection compound

• KPV (5mg / 10mg) – Anti-inflammatory tripeptide (found in KLOW variant)

• KLOW Blend (GHK-Cu + BPC-157 + TB-500 + KPV) – Four-peptide variant for inflammation-focused research

Frequently Asked Questions

What is GLOW? GLOW is a pre-formulated peptide blend containing three repair peptides: GHK-Cu (50mg), TB-500 (10mg), and BPC-157 (10mg) in a single vial. It is designed for research applications investigating tissue repair, inflammation, and extracellular matrix remodeling .

What does each component do?

• GHK-Cu: Copper-binding tripeptide; modulates gene expression, stimulates collagen synthesis, provides antioxidant protection 

• TB-500: Actin-regulating peptide; supports cell migration and angiogenesis 

• BPC-157: Repair signaling peptide; upregulates growth hormone receptors, promotes angiogenesis 

Why combine these three peptides? The three peptides target distinct phases of the repair cascade: BPC-157 fires the repair signal, TB-500 builds the infrastructure (cell migration, blood vessels), and GHK-Cu handles remodeling and structural quality. No single peptide covers all three phases .

Has the GLOW combination been studied in clinical trials? No. There are no published human clinical trials on this specific three-compound combination. The synergy logic is mechanistically coherent and extrapolated from component-level research .

What does the blue color mean? The deep blue color after reconstitution comes from the GHK-Cu copper chelate. It is a visual quality indicator that the blend has been properly reconstituted .

Is GLOW approved for human use? No. This product is for research purposes only and is not FDA-approved for human consumption, medical treatment, or veterinary applications. BPC-157 and TB-500 are on the WADA Prohibited List .

Do you provide a Certificate of Analysis? Yes. A lot-specific COA is available upon request for every vial shipped, including HPLC purity data and mass spectrometry confirmation for each component.